Selecta Biosciences, Inc., a Watertown, MA-based biopharmaceutical company developing synthetic nanoparticle vaccines, has raised $15m in a Series C financing round.
The round was led by OrbiMed Advisors LLC, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments.
This financing brings the total capital raised by Selecta over the past 15 months to more than $30m.
The capital infusion will enable the company to develop its synthetic vaccines for prophylactic and therapeutic indications based on its proprietary targeted Synthetic Vaccine Particle (tSVP™) platform.
The platform is based on biodegradable polymeric nanoparticles that integrate all the vaccine components for targeting to immune cells for optimal cellular or humoral immune response.
The company’s lead product candidate will enter human clinical evaluation in 2011.
In conjunction with the round, Dr. Gordon of OrbiMed will join Selecta’s board.